<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129075</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00898</org_study_id>
    <secondary_id>NCI-2014-00898</secondary_id>
    <secondary_id>CITN-07-FLT3L</secondary_id>
    <secondary_id>CITN-07-FLT3L</secondary_id>
    <secondary_id>CITN-07-FLT3L</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>U01CA154967</secondary_id>
    <nct_id>NCT02129075</nct_id>
  </id_info>
  <brief_title>A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma</brief_title>
  <official_title>A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-Treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a&#xD;
      biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma. The cancer&#xD;
      vaccine CDX-1401 attaches to a protein that is made in tumor cells. The vaccine helps the&#xD;
      body recognize the tumor to fight the cancer. The biologic drug CDX-301 may help the body&#xD;
      make more of the tumor fighting cells, known as dendritic cells. Another biologic drug,&#xD;
      poly-ICLC, may stimulate the immune system and help these dendritic cells mature so that they&#xD;
      can recognize the tumor. Giving CDX-301 may make the immune response to a combination of&#xD;
      CDX-1401 and poly-ICLC better.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether the immune response to NY-ESO-1 elicited by vaccination with&#xD;
      DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401) plus polyinosinic-polycytidylic acid&#xD;
      stabilized with poly-L-lysine and carboxymethylcellulose (poly-ICLC) is substantially&#xD;
      increased by prior expansion in the number of circulating dendritic cells (DC) by therapy&#xD;
      with recombinant Flt3 ligand (CDX-301) (fms-related tyrosine kinase 3 ligand [Flt3L]).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the effect of the vaccine regimen on immune responses to other ongoing and&#xD;
      nascent antitumor response antigens associated with melanoma (e.g., PRAME, MAGE-A3, p53, and&#xD;
      gp100) as well as memory viral responses (influenza A) and chronic viral responses&#xD;
      (cytomegalovirus [CMV], Epstein-Barr virus [EBV]).&#xD;
&#xD;
      II. To assess the effect of the vaccine regimen on the frequency and phenotypic character of&#xD;
      peripheral blood mononuclear cell (PBMC) subsets including DCs, monocyte populations, T&#xD;
      cells, and natural killer (NK) cells.&#xD;
&#xD;
      III. To assess the safety, tolerability, and clinical efficacy of the vaccine regimens.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive recombinant Flt3 ligand (CDX-301) subcutaneously (SC) on days -7 to&#xD;
      -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401&#xD;
      SC or intradermally (ID) on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle.&#xD;
      Treatment repeats every 28 days for 4 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days&#xD;
      for 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 and 12 weeks and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2014</start_date>
  <completion_date type="Actual">May 18, 2018</completion_date>
  <primary_completion_date type="Actual">March 28, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune T-cell Response to NY-ESO-1</measure>
    <time_frame>At 12 weeks after final vaccination</time_frame>
    <description>Response rates will be analyzed by tabulating the frequency of positive response for each assay by antigen and treatment arm at each time point for which an assessment is performed. Response rates will be presented with their corresponding 95% confidence interval estimates calculated using the score test method. Fisher's exact tests will be used to compare cohort 1 and cohort 2 at the peak time point, with a significant difference declared if the 1-sided P value is =&lt; 0.10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T Cell Responses to Other Ongoing and Nascent Antitumor Response Antigens Associated With Melanoma (e.g. PRAME, MAGE-A3, p53, and gp1000) as Well as Memory and Chronic Viral Responses (CMV, EBV)</measure>
    <time_frame>Up to 12 weeks after final vaccination</time_frame>
    <description>Response rates will be analyzed by tabulating the frequency of positive response for each assay by antigen and treatment arm at each time point for which an assessment is performed. Response rates will be presented with their corresponding 95% confidence interval estimates calculated using the score test method. Fisher's exact tests will be used to compare cohort 1 and cohort 2 at the peak time point, with a significant difference declared if the 1-sided P value is =&lt; 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold)</measure>
    <time_frame>Up to 12 weeks after final vaccination</time_frame>
    <description>Graphical and tabular summaries of the assay data will be made. Linear mixed effects model and possibly weighted generalized estimating equation methods will be considered for a supportive analysis of the longitudinal data over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Recurrence</measure>
    <time_frame>Up to 600 days from first vaccine</time_frame>
    <description>Time to first recurrence from first vaccine among subjects who have experienced recurrence. (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 1 year after patient's 12 week visit</time_frame>
    <description>Overall survival not assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cutaneous Melanoma</condition>
  <condition>Melanoma</condition>
  <condition>Melanoma of Unknown Primary</condition>
  <condition>Mucosal Melanoma</condition>
  <condition>Ocular Melanoma</condition>
  <condition>Stage IIB Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Stage IIC Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Stage III Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIA Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIB Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIC Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IV Cutaneous Melanoma AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Arm I (CDX-301, CDX-1401, poly-ICLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401 SC or ID on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (CDX-1401, poly-ICLC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DEC-205/NY-ESO-1 Fusion Protein CDX-1401</intervention_name>
    <description>Given SC or ID</description>
    <arm_group_label>Arm I (CDX-301, CDX-1401, poly-ICLC)</arm_group_label>
    <arm_group_label>Arm II (CDX-1401, poly-ICLC)</arm_group_label>
    <other_name>CDX-1401</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly ICLC</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (CDX-301, CDX-1401, poly-ICLC)</arm_group_label>
    <arm_group_label>Arm II (CDX-1401, poly-ICLC)</arm_group_label>
    <other_name>Hiltonol</other_name>
    <other_name>Poly I:Poly C with Poly-L-Lysine Stabilizer</other_name>
    <other_name>poly-ICLC</other_name>
    <other_name>PolyI:PolyC with Poly-L-Lysine Stabilizer</other_name>
    <other_name>Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose</other_name>
    <other_name>Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose</other_name>
    <other_name>Stabilized Polyriboinosinic/Polyribocytidylic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Flt3 Ligand</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (CDX-301, CDX-1401, poly-ICLC)</arm_group_label>
    <other_name>CDX-301</other_name>
    <other_name>FLT 3 Ligand</other_name>
    <other_name>FLT3 Ligand</other_name>
    <other_name>Flt3-Ligand</other_name>
    <other_name>Flt3L</other_name>
    <other_name>Mobist</other_name>
    <other_name>Mobista</other_name>
    <other_name>rhuFlt3L</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with fully resected stage IIb through IV melanoma, with melanoma validated by&#xD;
             histology or cytology, who have NOT received prior therapy.&#xD;
&#xD;
               -  Patients may have had primary cutaneous, mucosal, or ocular melanoma or&#xD;
                  metastasis from an unknown primary site.&#xD;
&#xD;
               -  Tissue should be submitted for evaluation of NY-ESO-1 expression and T-cell&#xD;
                  infiltrates. However, availability of tissue and/or positivity for NY-ESO-1 is&#xD;
                  not mandatory.&#xD;
&#xD;
          -  Prior radiation, chemotherapy or biologics NOT allowed&#xD;
&#xD;
          -  Not currently receiving any anticancer therapy&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
               -  Because no dosing or adverse event (AE) data are currently available on the use&#xD;
                  of CDX-1401 or CDX-301 in patients &lt; 18 years of age, children are excluded from&#xD;
                  this study, but will be eligible for future pediatric trials.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0-1&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,000/mcL&#xD;
&#xD;
          -  Platelets &gt;= 75,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 x institutional upper limit of normal (bilirubin &lt; 3 x&#xD;
             institutional upper limit of normal for Gilbert's syndrome)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 x institutional upper limit of normal OR creatinine clearance &gt;= 60&#xD;
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  The first six patients enrolled in the Flt3L arm of the study cannot be human&#xD;
             immunodeficiency virus (HIV)-positive. After the evaluation of safety in the first 6&#xD;
             patients, HIV-positive patients with adequate immune function as evidenced by stable&#xD;
             CD4 counts &gt;= 350/mm^3 are allowed to participate if the following criteria are met:&#xD;
&#xD;
               -  maintained on stable antiretroviral therapy with no significant drug&#xD;
                  interactions, and&#xD;
&#xD;
               -  no recent history of acquired immunodeficiency syndrome (AIDS) indicator&#xD;
                  conditions (&gt; 2 years from enrolling in trial), and&#xD;
&#xD;
               -  physician providing patient's care for HIV must also approve of patient entering&#xD;
                  the study&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             before the initiation of protocol therapy.&#xD;
&#xD;
               -  The effects of CDX-1401 or CDX-301 on the developing human fetus are unknown. For&#xD;
                  this reason, women of child-bearing potential and men must agree to use adequate&#xD;
                  contraception (hormonal or barrier method of birth control or abstinence) before&#xD;
                  study entry and for the duration of study participation. Should a woman become&#xD;
                  pregnant or suspect she is pregnant while she or her partner is participating in&#xD;
                  this study, she should inform her treating physician immediately. Men treated or&#xD;
                  enrolled on this protocol must also agree to use adequate contraception before&#xD;
                  the study, for the duration of study participation, and 4 months after completion&#xD;
                  of CDX-1401 or CDX-301 administration.&#xD;
&#xD;
               -  NOTE: Subjects are considered not of child-bearing potential if they are&#xD;
                  surgically sterile, they have undergone a hysterectomy, bilateral tubal ligation,&#xD;
                  or bilateral oophorectomy, or they are postmenopausal. Menopause is the age&#xD;
                  associated with complete cessation of menstrual cycles, menses, and implies the&#xD;
                  loss of reproductive potential. By a practical definition, it assumes menopause&#xD;
                  after 1 year without menses with an appropriate clinical profile at the&#xD;
                  appropriate age.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), or&#xD;
             ipilimumab before entering the study&#xD;
&#xD;
          -  Immunosuppressive therapy within 30 days prior to initiation of protocol therapy&#xD;
&#xD;
          -  Steroid therapy, or steroid therapy with more than 7 consecutive days of steroids&#xD;
             within the prior 4 weeks&#xD;
&#xD;
               -  The use of prednisone or equivalent &lt; 0.125 mg/kg/day (absolute maximum of 10&#xD;
                  mg/day) as replacement therapy is permitted&#xD;
&#xD;
               -  Inhaled or topical corticosteroids are permitted&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  Current or history of systemic autoimmune disease requiring systemic therapy.&#xD;
&#xD;
               -  NOTE: The following will not be exclusionary:&#xD;
&#xD;
                    -  The presence of laboratory evidence of autoimmune disease (e.g., positive&#xD;
                       antinuclear antibody [ANA] titer) without associated symptoms&#xD;
&#xD;
                    -  Clinical evidence of vitiligo&#xD;
&#xD;
                    -  Other forms of depigmenting illness&#xD;
&#xD;
          -  Cardiovascular disease that meets one of the following: congestive heart failure (New&#xD;
             York Heart Association Class III or IV), active angina pectoris, or recent myocardial&#xD;
             infarction (within the last 6 months)&#xD;
&#xD;
          -  Cirrhosis or chronic hepatitis C virus positivity or chronic hepatitis B infection&#xD;
&#xD;
               -  NOTE: A positive hepatitis B serology indicative of previous immunization (i.e.,&#xD;
                  hepatitis B virus surface antibody [HBsAb]-positive and hepatitis B virus core&#xD;
                  antibody [HBcAb]-negative), or a fully resolved acute hepatitis B virus infection&#xD;
                  is not an exclusion criterion&#xD;
&#xD;
          -  Known history of immunodeficiency disorder other than HIV-positive status&#xD;
&#xD;
          -  Extensive active brain disease including symptomatic brain metastases or presence of&#xD;
             leptomeningeal disease&#xD;
&#xD;
               -  NOTE: Patients with brain metastasis, after definitive therapy with surgery or&#xD;
                  stereotactic radiation and stable off steroids for &gt;= 4 weeks, are eligible&#xD;
&#xD;
          -  Other invasive cancers that are clinically active&#xD;
&#xD;
          -  Pregnancy or nursing or unwilling to take adequate birth control during therapy&#xD;
&#xD;
               -  NOTE: Pregnant women are excluded from this study because CDX-1401 or CDX-301 and&#xD;
                  poly-ICLC have an unknown potential for teratogenic or abortifacient effects.&#xD;
                  Because there is an unknown but potential risk for adverse events in nursing&#xD;
                  infants secondary to treatment of the mother with CDX-1401 or CDX-301,&#xD;
                  breastfeeding should be discontinued if the mother is treated with CDX-1401 or&#xD;
                  CDX-301 and poly-ICLC&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to CDX-1401 or CDX-301 or poly-ICLC&#xD;
&#xD;
          -  Prior organ allograft or allogeneic transplantation, if the transplanted tissue is&#xD;
             still in place&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Medical or psychiatric illness that would, in the opinion of the investigator,&#xD;
             preclude participation in the study or the ability of patients to provide informed&#xD;
             consent for themselves&#xD;
&#xD;
          -  History of pulmonary disease such as emphysema or chronic obstructive pulmonary&#xD;
             disease (COPD) (forced expiratory volume in 1 second [FEV1] &lt; 60% of predicted for&#xD;
             height and age). Pulmonary function tests (PFTs) are required in patients with&#xD;
             prolonged smoking history or symptoms of respiratory dysfunction&#xD;
&#xD;
          -  Vaccinations other than those given as part of this research study (with the exception&#xD;
             of influenza vaccine) are prohibited throughout the duration of study participation.&#xD;
&#xD;
               -  NOTE: Influenza vaccination (inactivated) is permitted during the flu season. The&#xD;
                  preferred time is 7 to 14 days after CDX-1401 administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Bhardwaj</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Immunotherapy Trials Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>November 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2021</results_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly I-C</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
    <mesh_term>Flt3 ligand protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No enrolled participants were excluded from the study before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
          <description>Patients receive recombinant flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
        </group>
        <group group_id="P2">
          <title>Arm II (CDX-1401 and Poly-ICLC)</title>
          <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
          <description>Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
        </group>
        <group group_id="B2">
          <title>Arm II (CDX-1401 and Poly-ICLC)</title>
          <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="13.4"/>
                    <measurement group_id="B2" value="51.6" spread="14.5"/>
                    <measurement group_id="B3" value="53.1" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immune T-cell Response to NY-ESO-1</title>
        <description>Response rates will be analyzed by tabulating the frequency of positive response for each assay by antigen and treatment arm at each time point for which an assessment is performed. Response rates will be presented with their corresponding 95% confidence interval estimates calculated using the score test method. Fisher's exact tests will be used to compare cohort 1 and cohort 2 at the peak time point, with a significant difference declared if the 1-sided P value is =&lt; 0.10.</description>
        <time_frame>At 12 weeks after final vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
            <description>Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (CDX-1401 and Poly-ICLC)</title>
            <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Immune T-cell Response to NY-ESO-1</title>
          <description>Response rates will be analyzed by tabulating the frequency of positive response for each assay by antigen and treatment arm at each time point for which an assessment is performed. Response rates will be presented with their corresponding 95% confidence interval estimates calculated using the score test method. Fisher's exact tests will be used to compare cohort 1 and cohort 2 at the peak time point, with a significant difference declared if the 1-sided P value is =&lt; 0.10.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T Cell Responses to Other Ongoing and Nascent Antitumor Response Antigens Associated With Melanoma (e.g. PRAME, MAGE-A3, p53, and gp1000) as Well as Memory and Chronic Viral Responses (CMV, EBV)</title>
        <description>Response rates will be analyzed by tabulating the frequency of positive response for each assay by antigen and treatment arm at each time point for which an assessment is performed. Response rates will be presented with their corresponding 95% confidence interval estimates calculated using the score test method. Fisher's exact tests will be used to compare cohort 1 and cohort 2 at the peak time point, with a significant difference declared if the 1-sided P value is =&lt; 0.10.</description>
        <time_frame>Up to 12 weeks after final vaccination</time_frame>
        <population>T cell responses to MAGE-A3 and PRAME; positive at any timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
            <description>Patients receive recombinant flt3 ligand SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (CDX-1401 and Poly-ICLC)</title>
            <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>T Cell Responses to Other Ongoing and Nascent Antitumor Response Antigens Associated With Melanoma (e.g. PRAME, MAGE-A3, p53, and gp1000) as Well as Memory and Chronic Viral Responses (CMV, EBV)</title>
          <description>Response rates will be analyzed by tabulating the frequency of positive response for each assay by antigen and treatment arm at each time point for which an assessment is performed. Response rates will be presented with their corresponding 95% confidence interval estimates calculated using the score test method. Fisher's exact tests will be used to compare cohort 1 and cohort 2 at the peak time point, with a significant difference declared if the 1-sided P value is =&lt; 0.10.</description>
          <population>T cell responses to MAGE-A3 and PRAME; positive at any timepoint</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold)</title>
        <description>Graphical and tabular summaries of the assay data will be made. Linear mixed effects model and possibly weighted generalized estimating equation methods will be considered for a supportive analysis of the longitudinal data over time.</description>
        <time_frame>Up to 12 weeks after final vaccination</time_frame>
        <population>Only a subset of patient specimens were needed to meet statistical power. 15 participants were analyzed in Arm I (CDX-301, CDX-1401, and poly-ICLC and 16 participants were analyzed in Arm II (CDX-1401 and poly-ICLC). One less patient in Arm 1 was analyzed due to sample quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
            <description>Patients receive recombinant flt3 ligand SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (CDX-1401 and Poly-ICLC)</title>
            <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold)</title>
          <description>Graphical and tabular summaries of the assay data will be made. Linear mixed effects model and possibly weighted generalized estimating equation methods will be considered for a supportive analysis of the longitudinal data over time.</description>
          <population>Only a subset of patient specimens were needed to meet statistical power. 15 participants were analyzed in Arm I (CDX-301, CDX-1401, and poly-ICLC and 16 participants were analyzed in Arm II (CDX-1401 and poly-ICLC). One less patient in Arm 1 was analyzed due to sample quality.</population>
          <units>log 2 fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cDCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="16.98"/>
                    <measurement group_id="O2" value="0.9" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.11"/>
                    <measurement group_id="O2" value="1.0" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.28"/>
                    <measurement group_id="O2" value="1.1" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK CD56br cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.84"/>
                    <measurement group_id="O2" value="1.26" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.36"/>
                    <measurement group_id="O2" value="1.0" spread=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pDC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="7.27"/>
                    <measurement group_id="O2" value="0.8" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Recurrence</title>
        <description>Time to first recurrence from first vaccine among subjects who have experienced recurrence. (days)</description>
        <time_frame>Up to 600 days from first vaccine</time_frame>
        <population>Analysis is reported for the number of subjects with recurrence (N=12 Arm I) (N=9 Arm II)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
            <description>Patients receive recombinant flt3 ligand SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (CDX-1401 and Poly-ICLC)</title>
            <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Recurrence</title>
          <description>Time to first recurrence from first vaccine among subjects who have experienced recurrence. (days)</description>
          <population>Analysis is reported for the number of subjects with recurrence (N=12 Arm I) (N=9 Arm II)</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.3" spread="191.1"/>
                    <measurement group_id="O2" value="389.2" spread="223.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival not assessed</description>
        <time_frame>Up to 1 year after patient's 12 week visit</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
            <description>Patients receive recombinant flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (CDX-1401 and Poly-ICLC)</title>
            <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival not assessed</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Systematic evaluation by clinicaltrials.gov definition</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (CDX-301, CDX-1401, and Poly-ICLC)</title>
          <description>Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies&#xD;
Recombinant Flt3 Ligand: Given SC</description>
        </group>
        <group group_id="E2">
          <title>Arm II (CDX-1401 and Poly-ICLC)</title>
          <description>Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
DEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given SC or ID&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Neoantigen-based Melanoma-Poly-ICLC Vaccine: Given SC&#xD;
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, puerperium and perinatal conditions</sub_title>
                <counts group_id="E1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="30" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="37" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="44" subjects_affected="17" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Injection site reactions</description>
                <counts group_id="E1" events="509" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" events="322" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="43" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" events="49" subjects_affected="14" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="51" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="28" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="56" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E2" events="33" subjects_affected="18" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="35" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E2" events="49" subjects_affected="19" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, puerperium and perinatal conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="24" subjects_affected="13" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="26" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Martin A. Cheever</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-4141</phone>
      <email>mcheever@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

